2BBBullish & Bearish
Fractyl Health, Inc. (GUTS) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 23 out of 100.
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.
Fractyl Health, Inc.’s current 2BB score is 23 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 2 | Very Weak |
| Quality | 80 | Very Strong |
| Risk | 53 | Moderate |
| Headquarters | Burlington, Massachusetts, United States |
| Founded | 2010 |
| Employees | 100 |
| 52-week range | $0.38 – $2.44 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-08-10 | -0.12 | -0.1377 | $0.00 | $0.00 |
| 2026-05-12 | -0.13 | -0.1632 | $0.00 | $0.00 |
| 2026-03-24 | -0.07 | -0.1836 | $0.00 | $0.00 |